Journal of Pathology and Translational Medicine (대한병리학회지)

The Korean Society of Pathologists (대한병리학회)
권호 표지

A High Thymidylate Synthase Expression is Related to Better Outcome for Advanced Gastric Cancer Patients Treated with 5-FU Chemotherapy after Curative Resection

Cho, Mee-Yon;Yi, Sang-Yeop;Eom, Minseob;Zhang, Shu-Peng;Kim, Hwan-Sik;Lee, Jong-In;Kim, Dae-Sung

  • Published : 20060400
⟨ Previous Next ⟩

Abstract

Background : The expressions of thymidylate synthase (TS), E2F-1, pRb, and p53 are correlated with DNA synthesis. The significance of their expressions is still controversial for predicting the outcome of 5-fluorouracil (5-FU) therapy in the patients with advanced gastric carcinoma. Furthermore, their prognostic value in the metastatic lesions of gastric carcinoma has not yet been confirmed. Methods : To ascertain their prognostic value, we immunohistochemically analyzed the expressions of TS, E2F-1, pRb, and p53 in the primary tumors and the related metastatic lymph nodes, and we then compared the survival between the high and low expression group of each protein. Ninety four patients with advanced gastric carcinoma who were treated by complete resection and adjuvant 5-FU chemotherapy were analyzed. Results : The TS expression in primary tumors was significantly correlated with that of E2F-1. The expression of these genes showed no significant difference between the primary tumors and the metastatic lymph nodes except for E2F-1, which was significantly higher in the lymph node metastasis than in the primary tumors. After complete resection and 5-FU-based adjuvant chemotherapy, patients with a high TS expression in the primary tumors showed a longer survival than those patients having primary tumors with a low TS expression (p=0.0392). Conclusion : A high TS expression in the primary tumors may be related to a better outcome for advanced gastric cancer patients who were treated with 5-FU chemotherapy after curative resection.

Keywords

References

  1. Lee HJ, Yang HK, Ahn YO. Gastric cancer in Korea. Gastric Cancer 2002; 5: 177-82 https://doi.org/10.1007/s101200200031
  2. Yao JC, Mansfield PF, Pisters PW, et al. Combined-modality therapy for gastric cancer. Semin Surg Oncol 2003; 21: 223-7 https://doi.org/10.1002/ssu.10040
  3. Danenberg PV. Thymidylate synthase: a target-enzyme in cancer chemotherapy. Biochem Biophys Acta 1977; 473: 73-92
  4. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13: 471-81 https://doi.org/10.1021/bi00700a012
  5. Tsujitani S, Konishi I, Suzuki K, et al. Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients. J Exp Clin Cancer Res 2000; 19: 189-95
  6. Formentini A, Henne-Bruns D, Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbecks Arch Surg 2004; 389: 405-13 https://doi.org/10.1007/s00423-004-0510-y
  7. Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 2001; 10: 257- 69
  8. Aschele C, Debernardis D, Tunesi G, Maley F, Sobrerc A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 2000; 6: 4797-802
  9. Gorlick R, Metzger R, Danenberg KD, et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 1998; 16: 1465-9 https://doi.org/10.1200/JCO.1998.16.4.1465
  10. Trocha SD, Saha SS, Wiese D, Thompson J, Morton DL, Bilchik AJ. Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes : impact on adjuvant treatment. Am Surg 2003; 69: 918-22
  11. Kuniyasu T, Nakamura T, Tabuchi Y, Kuroda Y. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody : the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 1998; 83: 1300-6 https://doi.org/10.1002/(SICI)1097-0142(19981001)83:7<1300::AID-CNCR5>3.0.CO;2-M
  12. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258: 424-9 https://doi.org/10.1126/science.1411535
  13. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998; 9: 585-93
  14. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res 1998; 58: 4292-6
  15. Banerjee D, Gorlick R, Liefshitz A, et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res 2000; 60: 2365-7
  16. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-6 https://doi.org/10.1038/358015a0
  17. Longley DB, Boyer J, Allen WL, et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 2002; 62: 2644-9
  18. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263-9 https://doi.org/10.1172/JCI6863
  19. Frederick LG, David LP, Irvin DF, et al. AJCC cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002, 99-102
  20. Kumar B, De Silva M, Venter DJ, Armes JE. Tissue microarrays: a practical guide. Pathology 2004; 36: 295-300 https://doi.org/10.1080/00313020410001721555
  21. Lauren P. The two histological main types of gastric carcinoma: diffuse and socalled intestinal type carcinoma. An attempt at a histological classification. Acta Pathol Microbiol Scand 1965; 64: 34
  22. Longley DB, McDermott U, Johnston PG. Clinical significance of prognostic and predictive markers in colorectal cancer. Pharmacogenomics J 2002; 2: 209-16 https://doi.org/10.1038/sj.tpj.6500124
  23. Bates S, Phillips AC, Clark PA, et al. p14ARF links the tumour suppressors RB and p53. Nature 1998; 395: 124-5 https://doi.org/10.1038/25867
  24. Broll R, Busch P, Duchrow M, et al. Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer. Int J Colorectal Dis 2005; 20: 94-102 https://doi.org/10.1007/s00384-004-0621-5
  25. Min BW, Hong JH, Lee KB, Moon HY. Significance of thymidylate synthase expression in colorectal cancer. J Korean Surg Soc 2002; 62: 408-14
  26. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 529-36 https://doi.org/10.1200/JCO.2004.05.064
  27. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-9 https://doi.org/10.1016/S0140-6736(98)07127-X
  28. Johnstone PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-7 https://doi.org/10.1200/JCO.1994.12.12.2640
  29. Nam EM, Im SA, Lee SN, Koo HS. The relationship between thymidylate synthase expression and prognosis in gastric adenocarcinoma. Korean J Med 1999; 56: 339-46
  30. Ishida Y, Kawakami K, Tanaka Y, Kanehira E, Omura K, Watanabe G. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 2002; 22: 2805-9